Compare Stocks: GOVX, GDTC, INAB, and LSTA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GDTC CytoMed Therapeutics	$0.94 -6.5%	$0.96	$0.68 ▼ $3.68	$11.83M	0.04	49,438 shs	27,600 shs
GOVX GeoVax Labs	$0.64 -6.5%	$0.95	$0.59 ▼ $20.00	$2.38M	3.73	951,706 shs	730,646 shs
INAB IN8bio	$1.17 -0.8%	$1.25	$0.88 ▼ $2.73	$11.63M	0.24	81,417 shs	58,728 shs
LSTA Lisata Therapeutics	$1.74 -1.1%	$2.34	$0.99 ▼ $5.07	$15.86M	0.88	502,739 shs	184,256 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GDTC CytoMed Therapeutics	-6.50%	-0.49%	-5.56%	-22.08%	-52.30%
GOVX GeoVax Labs	-6.47%	-1.32%	-12.21%	-75.96%	-96.61%
INAB IN8bio	-0.85%	+2.63%	-2.50%	-35.00%	-46.58%
LSTA Lisata Therapeutics	-1.14%	+51.30%	+4.19%	-47.27%	-31.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GDTC CytoMed Therapeutics	$0.94 -6.5%	$0.96	$0.68 ▼ $3.68	$11.83M	0.04	49,438 shs	27,600 shs
GOVX GeoVax Labs	$0.64 -6.5%	$0.95	$0.59 ▼ $20.00	$2.38M	3.73	951,706 shs	730,646 shs
INAB IN8bio	$1.17 -0.8%	$1.25	$0.88 ▼ $2.73	$11.63M	0.24	81,417 shs	58,728 shs
LSTA Lisata Therapeutics	$1.74 -1.1%	$2.34	$0.99 ▼ $5.07	$15.86M	0.88	502,739 shs	184,256 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GDTC CytoMed Therapeutics	-6.50%	-0.49%	-5.56%	-22.08%	-52.30%
GOVX GeoVax Labs	-6.47%	-1.32%	-12.21%	-75.96%	-96.61%
INAB IN8bio	-0.85%	+2.63%	-2.50%	-35.00%	-46.58%
LSTA Lisata Therapeutics	-1.14%	+51.30%	+4.19%	-47.27%	-31.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GDTC CytoMed Therapeutics	1.00	Sell	N/A	N/A
GOVX GeoVax Labs	1.50	Reduce	$150.00	23,268.13% Upside
INAB IN8bio	2.00	Hold	$4.00	241.88% Upside
LSTA Lisata Therapeutics	1.67	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest GOVX, GDTC, INAB, and LSTA Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/13/2026	LSTA Lisata Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	LSTA Lisata Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	GOVX GeoVax Labs	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	INAB IN8bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	LSTA Lisata Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	GDTC CytoMed Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/4/2026	INAB IN8bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GDTC CytoMed Therapeutics	$250K	44.24	N/A	N/A	$0.45 per share	2.08
GOVX GeoVax Labs	$2.49M	0.89	N/A	N/A	$0.51 per share	1.26
INAB IN8bio	N/A	N/A	N/A	N/A	$1.86 per share	N/A
LSTA Lisata Therapeutics	$170K	92.22	N/A	N/A	$0.89 per share	1.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GDTC CytoMed Therapeutics	-$3.10M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	11/13/2026 (Estimated)
GOVX GeoVax Labs	-$21.47M	-$11.34	N/A	N/A	N/A	N/A	-743.64%	-394.74%	11/12/2026 (Estimated)
INAB IN8bio	-$19.44M	-$1.62	N/A	N/A	N/A	N/A	-91.18%	-76.93%	11/5/2026 (Estimated)
LSTA Lisata Therapeutics	-$16.59M	-$1.64	N/A	N/A	N/A	N/A	-116.08%	-90.55%	11/5/2026 (Estimated)

Latest GOVX, GDTC, INAB, and LSTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2026	Q2 2026	INAB IN8bio	-$0.3437	-$0.25	+$0.0937	-$0.25	N/A	N/A
7/27/2026	Q2 2026	GOVX GeoVax Labs	-$2.16	-$0.97	+$1.19	-$0.97	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GDTC CytoMed Therapeutics	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A
INAB IN8bio	N/A	N/A	N/A	N/A	N/A
LSTA Lisata Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GDTC CytoMed Therapeutics	0.06	5.17	5.17
GOVX GeoVax Labs	N/A	1.54	1.54
INAB IN8bio	N/A	8.21	8.21
LSTA Lisata Therapeutics	N/A	3.69	3.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GDTC CytoMed Therapeutics	0.04%
GOVX GeoVax Labs	6.09%
INAB IN8bio	92.05%
LSTA Lisata Therapeutics	8.94%

Insider Ownership

Company	Insider Ownership
GDTC CytoMed Therapeutics	N/A
GOVX GeoVax Labs	0.69%
INAB IN8bio	14.50%
LSTA Lisata Therapeutics	9.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GDTC CytoMed Therapeutics	N/A	11.83 million	N/A	Not Optionable
GOVX GeoVax Labs	10	3.47 million	3.45 million	Not Optionable
INAB IN8bio	20	9.86 million	8.43 million	Not Optionable
LSTA Lisata Therapeutics	30	9.01 million	8.19 million	Not Optionable

GOVX, GDTC, INAB, and LSTA Headlines

Recent News About These Companies

Lisata Therapeutics moves forward with legal action following Kuva merger termination

August 4, 2026 | proactiveinvestors.com

Lisata Therapeutics moves forward with legal action following Kuva merger termination

August 4, 2026 | proactiveinvestors.com

Lisata Therapeutics Files Suit Against Kuva Labs, Reviews Strategic Alternatives and Cuts Workforce to Preserve Cash

August 4, 2026 | quiverquant.comQ

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

August 4, 2026 | globenewswire.com

Lisata Therapeutics stock falls after hours: Here's why

July 23, 2026 | msn.com

Lisata Therapeutics Extends Merger Timeline with Kuva Labs

July 17, 2026 | tipranks.com

Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing

June 26, 2026 | globenewswire.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)

June 15, 2026 | newsfilecorp.comN

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)

June 15, 2026 | newsfilecorp.comN

Lisata Therapeutics, Inc.: Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

June 10, 2026 | finanznachrichten.de

Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share

June 10, 2026 | proactiveinvestors.com

Lisata Therapeutics Announces Tender Offer from Kuva Acquisition Corp at $4.00 per Share Plus Contingent Value Rights

June 10, 2026 | quiverquant.comQ

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

June 10, 2026 | globenewswire.com

Kuva and Lisata Therapeutics Tender Offer Update

June 1, 2026 | tennessean.comT

HC Wainwright & Co. downgrades Lisata Therapeutics (LSTA)

May 16, 2026 | msn.com

Lisata Therapeutics Amends Kuva Labs Merger Agreement Timeline

May 9, 2026 | theglobeandmail.com

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders

May 4, 2026 | globenewswire.com

Lisata Therapeutics Delays Tender Offer Launch in Merger

April 3, 2026 | tipranks.com

Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications

March 26, 2026 | businesswire.com

Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances

March 10, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GOVX, GDTC, INAB, and LSTA Company Descriptions

CytoMed Therapeutics NASDAQ:GDTC

$0.94 -0.07 (-6.50%)

Closing price 08/25/2026 03:59 PM Eastern

Extended Trading

$0.92 -0.02 (-2.03%)

As of 08/25/2026 04:01 PM Eastern

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

GeoVax Labs NASDAQ:GOVX

$0.64 -0.04 (-6.47%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$0.64 -0.01 (-0.92%)

As of 08/25/2026 05:41 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

IN8bio NASDAQ:INAB

$1.17 -0.01 (-0.85%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$1.18 +0.01 (+0.43%)

As of 08/25/2026 04:10 PM Eastern

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.

Lisata Therapeutics NASDAQ:LSTA

$1.74 -0.02 (-1.14%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$1.75 +0.01 (+0.69%)

As of 08/25/2026 05:40 PM Eastern

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GOVX, GDTC, INAB, and LSTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GOVX, GDTC, INAB, and LSTA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GOVX, GDTC, INAB, and LSTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GOVX, GDTC, INAB, and LSTA Company Descriptions

CytoMed Therapeutics NASDAQ:GDTC

GeoVax Labs NASDAQ:GOVX

IN8bio NASDAQ:INAB

Lisata Therapeutics NASDAQ:LSTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GOVX, GDTC, INAB, and LSTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GOVX, GDTC, INAB, and LSTA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GOVX, GDTC, INAB, and LSTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GOVX, GDTC, INAB, and LSTA Company Descriptions

CytoMed Therapeutics NASDAQ:GDTC

GeoVax Labs NASDAQ:GOVX

IN8bio NASDAQ:INAB

Lisata Therapeutics NASDAQ:LSTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools